Tag Archives: Pfizer says Covid-19 vaccine 90% effective in Phase three trial

A vaccine jointly developed by Pfizer and BioNTech was 90 percent effective in preventing Covid-19 infections in ongoing Phase 3 trials, the companies announced Monday. Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings. “The first set of results from our Phase 3 Covid-19 vaccine trial …

Read More »